Greetings all, hopped over from the cydy board and traded a few cydy shares for some GNBT after reading the recent seeking alpha article and listening to the October conference call.

Wow, Malaysia deal at 2.6 million up front that fully funds the current covid testing (is my understanding), mgmt that is underpaid, likely nasdaq spin off of the vaccine arm. Sinopharm deal in the works was 5 mil up front but now that they want cancer and swine flu it will be more?

Basically they are on track to have up front licensing fees almost equal to their current mkt cap. Am I missing something? That seems almost too good to be true. The biggest hurdle pre-revs have is money to get them to the next step. Sounds like gnbt has that...and potentially more.

Sorry, posting stuff you all already know, but I'm a newbie on this board and interested to see where this may go. Hoping my trade of 4k cydy shares for 50k of gnbt turns up roses. I'll go quiet now, and learn from the long timers here.